Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402662 · ClinicalTrials.gov registry record · Phase 2
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00402662 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 3 participants.
The verdict
NCT00402662, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer, and to determine the side effects of the combination in patients with melanoma. Each of the drugs in this combination, if used alone, would not be expected to have an effect against the cancer. However, when used together, there is a possibility that they could work together to damage the cancer cells, or to block the formation or function of the blood vessels that feed the cancer, either of which could result in slowing the growth of or shrinking the cancer. Both drugs work by blocking signals that are sent from outside of a cell to the inside of the cell that direct the cell to make certain substances to keep the cell alive. Cancer cells or blood vessels that feed cancer cells may be more sensitive to drugs that block these signals.
Interventions
- DRUG Imatinib
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402662
The ClinicalTrials.gov registry entry for NCT00402662 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib is the first listed.
NCT00402662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402662 about?
NCT00402662 is a clinical study titled "A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma". The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer, and to determine the side effects of the combination in patients with melanoma. Each of the drugs in this combination, if used alone, would ...
What is the current status of trial NCT00402662?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-02. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00402662?
The interventions under investigation include: Imatinib (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT00402662?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.